Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • TA228
  • Published: 

Multiple myeloma: register to attend the appeal

The Institute has received one appeal against the Final Appraisal Determination and Guidance on this technology. The Institute has arranged the hearing for the appeal received against the FAD for the above technology. The appeal panel will convene on Monday 15 November 2010 to hear oral representations from the appellants.

The registration period for this appeal has now passed.

This page was last updated: 24 September 2010